|
|
|
|
LEADER |
00000cam a2200000 a 4500 |
001 |
SCIDIR_on1155408566 |
003 |
OCoLC |
005 |
20231120010453.0 |
006 |
m o d |
007 |
cr |n||||||||| |
008 |
200526s2020 mau ob 000 0 eng d |
040 |
|
|
|a YDX
|b eng
|e pn
|c YDX
|d OPELS
|d OHS
|d OCLCO
|d EBLCP
|d CUS
|d UKMGB
|d OCLCA
|d VT2
|d OCLCO
|d OCLCQ
|d COM
|d OCLCO
|d OCLCF
|d OCLCQ
|d OCLCO
|
015 |
|
|
|a GBC062887
|2 bnb
|
015 |
|
|
|a GBC061323
|2 bnb
|
016 |
7 |
|
|a 019801768
|2 Uk
|
019 |
|
|
|a 1155599216
|a 1281716391
|a 1286908326
|
020 |
|
|
|a 9780128211151
|q (electronic bk.)
|
020 |
|
|
|a 0128211156
|q (electronic bk.)
|
020 |
|
|
|z 9780128211144
|
020 |
|
|
|z 0128211148
|
035 |
|
|
|a (OCoLC)1155408566
|z (OCoLC)1155599216
|z (OCoLC)1281716391
|z (OCoLC)1286908326
|
050 |
|
4 |
|a RC280.B7
|
060 |
|
4 |
|a W1
|b IN834 v.151 2020
|
060 |
|
4 |
|a QZ 380
|
082 |
0 |
4 |
|a 616.99/481
|2 23
|
245 |
0 |
0 |
|a Novel therapeutic advances in glioblastoma /
|c edited by Igor Bryukhovetskiy, Aruna Sharma, Zhiqiang Zhang, Hari Shanker Sharma.
|
260 |
|
|
|a Cambridge, MA :
|b Academic Press,
|c 2020.
|
300 |
|
|
|a 1 online resource
|
336 |
|
|
|a text
|b txt
|2 rdacontent
|
337 |
|
|
|a computer
|b c
|2 rdamedia
|
338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
490 |
1 |
|
|a International review of neurobiology ;
|v v. 151
|
505 |
0 |
|
|a Intro -- Novel Therapeutic Advances in Glioblastoma -- Copyright -- Contents -- Contributors -- Preface -- References -- Acknowledgments -- Chapter One: Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine -- 1. Introduction -- 1.1. History of glioblastoma -- 2. The blood-brain barrier and brain tumors -- 2.1. The blood-brain barrier structure and function -- 2.1.1. The BBB microenvironment -- 2.1.2. Adsorptive mediated BBB transport -- 2.1.3. Carrier mediated BBB transport -- 2.1.4. Receptor mediated BBB transport
|
505 |
8 |
|
|a 2.1.5. The blood-brain barrier function in physiological conditions -- 3. The blood-tumor barrier structure and function -- 3.1. The blood-tumor barrier -- 3.2. The blood-tumor barrier heterogeneity -- 4. Therapeutic strategies for brain tumor -- 4.1. Glioma stem cell and resistance and BT therapy -- 4.1.1. Pathogenesis of glioblastoma -- 4.2. Bacterial toxins and viral vectors for novel glioma therapy -- 4.2.1. Viral infections and cancer -- 4.2.2. Bacterial infection and cancer -- 4.2.3. Viral genome modification and glioblastoma treatment -- 4.2.4. Viral vectors and glioblastoma treatment
|
505 |
8 |
|
|a 4.3. Enhanced drug delivery through the blood-brain and blood-tumor barriers -- 4.3.1. Modulation of influx transport at BTB/BBB -- 4.3.2. Modulation of efflux transporters at BTB/BBB -- 4.3.3. Stem cell induced drug delivery at the BTB/BBB -- 5. Nano-drug delivery for brain tumor therapy -- 5.1. Nanodelivery of drugs and enhanced permeability and retention -- 5.1.1. Active tumor targeting by nanoparticles -- 5.1.2. Nanoparticles for treating brain tumor stem cells -- 5.1.3. Nanoparticles and glioma resistance factor -- 6. Theranostic nanomedicine for brain tumor therapy
|
505 |
8 |
|
|a 6.1. Multifunctionalized nanoplatforms -- 7. Our experiments with nanowired delivery of drugs in experimental glioma -- 7.1. Induction of primary glioma -- 7.1.1. Plasma biomarker of rat brain glioma -- 7.1.2. Measurement of VEGF-121 in plasma of rat brain glioma -- 7.1.3. Nanodelivery of drugs using TiO2 nanowires for rat glioma -- 7.1.4. Nanodelivery of drugs reduces pathophysiology of rat brain glioma -- 8. Possible mechanisms of nanowired drug delivery on neuroprotection in rat glioma -- 9. Conclusion and future direction -- Acknowledgments -- References
|
505 |
8 |
|
|a Chapter Two: Personalized therapy and stem cell transplantation for pro-inflammatory modulation of cancer stem cells micr ... -- 1. Introduction -- 2. Modern standards for GBM treatment and reasons for their inefficiency -- 3. BBB and treatment resistance -- 4. Nano-based drug delivery -- 5. Genotoxic pharmacotherapy and methods for optimization -- 6. CSCs and personalized therapy -- 7. Normal stem cells and treatment resistance -- 8. CSCs and well-differentiated non-tumor cells in GBM
|
504 |
|
|
|a Includes bibliographical references.
|
520 |
|
|
|a "Novel Therapeutic Advances in Glioblastoma, Volume 151 in the International Review of Neurobiology series, highlights new advances in the field, with this new volume presenting interesting chapters on a variety of topics, including Blood-brain barrier and pathophysiology of brain tumors, Promising strategies of glioblastoma treatment: personalized genotoxic therapy and stem cell transplantation, Extracellular matrix and biocompatible materials in glioblastoma treatment, Expression of Twist associated to microcirculation patterns of human glioma correlated with progression and survival of the patient, Advanced Multimodal Imaging in Differentiating Glioma Recurrence from Post-radiotherapy Changes, Advanced Multimodal Imaging in Differentiating Glioma Recurrence from Post-radiotherapy Changes, and much more."--Publisher's web page, viewed May 25, 2020
|
650 |
|
0 |
|a Gliomas
|x Treatment
|x Technological innovations.
|
650 |
|
0 |
|a Gliomas.
|
650 |
|
2 |
|a Brain Neoplasms
|0 (DNLM)D001932
|
650 |
|
2 |
|a Glioma
|0 (DNLM)D005910
|
650 |
|
6 |
|a Gliome
|0 (CaQQLa)201-0088792
|x Traitement
|0 (CaQQLa)201-0375123
|x Innovations.
|0 (CaQQLa)201-0375123
|
650 |
|
6 |
|a Gliome.
|0 (CaQQLa)201-0088792
|
650 |
|
7 |
|a Gliomas
|2 fast
|0 (OCoLC)fst00943446
|
700 |
1 |
|
|a Bryukhovetskiy, Igor,
|e editor.
|
700 |
1 |
|
|a Sharma, Aruna,
|c MD,
|e editor.
|
700 |
1 |
|
|a Zhang, Zhiqiang,
|e editor.
|
700 |
1 |
|
|a Sharma, H. S.
|q (Hari Shanker),
|e editor.
|
776 |
0 |
8 |
|i Print version:
|t Novel therapeutic advances in glioblastoma.
|d Cambridge, MA : Academic Press, 2020
|z 0128211148
|z 9780128211144
|w (OCoLC)1127099252
|
830 |
|
0 |
|a International review of neurobiology ;
|v v. 151.
|
856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/151
|z Texto completo
|